Tissue plasminogen activator (tPA) is the most commonly used drug in this setting after assessing that the patient does not present any major contraindication to its use, such as recent major thoracic or abdominal surgery as well as proven intracranial processes like neoplasms or stroke. This evidence concerns the gene PLAT and neoplasm.